Vandraas KF, Hjorth S, Trewin-Nybråten CB, Andreassen BK, Blix ES, Naume B, Botteri E, Ursin G, Støer NC(2026) Translating CLEOPATRA into routine practice: National treatment patterns and survival for patients with HER2-positive metastatic breast cancer Breast, 89, 104852(in press) DOI 10.1016/j.breast.2026.104852, PubMed 42385477
Pagani O, Niman SM, Ruggeri M, Peccatori FA, Azim HA, Colleoni M, Saura C, Shimizu C, Sætersdal AB, Kroep JR, Warner E, Amant F, Mailliez A, Moore HCF, Ruiz-Borrego M, Walshe JM, Borges VF, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Saunders C, Bjelic-Radisic Vet al.(2026) Updated results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) trial Ann Oncol(in press) DOI 10.1016/j.annonc.2026.05.699, PubMed 42214557
Ailte I, Chauhan SK, Prasmickaite L, Bassarova AV, Poissonnier A, Feenstra M, Nyakas M, Johannessen B, Ryder T, Hermann R, Frich L, Holth A, Inderberg EM, Jespersen H, Flørenes VA, Kyte JA, Mælandsmo GM, Egeland EV(2026) CD38hiCD19dim cells in lymph nodes predict favorable prognosis in patients with stage III melanoma receiving adjuvant PD-1-blockade Front Oncol, 16, 1815008 DOI 10.3389/fonc.2026.1815008, PubMed 42158424
